YS Biopharma (YS) Set to Announce Quarterly Earnings on Friday

YS Biopharma (NASDAQ:YS) is scheduled to be posting its quarterly earnings results before the market opens on Friday, April 19th.

YS Biopharma (NASDAQ:YS) last announced its earnings results on Monday, January 22nd. The company reported ($0.16) EPS for the quarter. The business had revenue of $13.64 million for the quarter. On average, analysts expect YS Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

YS Biopharma Price Performance

NASDAQ YS opened at $0.94 on Thursday. The company has a 50 day simple moving average of $0.62 and a 200-day simple moving average of $0.57. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.09. YS Biopharma has a 52-week low of $0.35 and a 52-week high of $2.37.

Hedge Funds Weigh In On YS Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC bought a new position in shares of YS Biopharma in the first quarter valued at approximately $1,864,000. Barclays PLC bought a new position in shares of YS Biopharma during the second quarter valued at $150,000. Finally, XTX Topco Ltd bought a new position in shares of YS Biopharma in the second quarter valued at about $31,000. Institutional investors own 52.64% of the company’s stock.

About YS Biopharma

YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.